Who are Adipo Therapeutics's investors?

Adipo Therapeutics's investors include Elevate Ventures, IU Ventures, Riverbend Capital.

How much funding has Adipo Therapeutics raised?

Adipo Therapeutics has disclosed $6M raised across 2 of its 3 known rounds.

Where is Adipo Therapeutics headquartered?

Adipo Therapeutics is headquartered in Indianapolis, US.

Adipo Therapeutics

Indianapolis, US · Founded 2016 · Indiana LLC · 5 known investors

Biotech

Founders & leadership

Keith JohnsExecutive

Karen WursterExecutive

Meng DengNamed on SEC filing

Board

Michael ClaymanBoard director

Investors · 5

Elevate VenturesIndianapolis · $20K – $2M

IU VenturesBloomington

Riverbend CapitalWashington

Also in the syndicate · 2

Purdue Research FoundationVisionTech Partners

Funding

SEC filings, press & company announcements

$6M disclosed across 2 of 3 rounds · 2020–2024

Undisclosed amountbridge funding roundJan 2024
Elevate Ventures, IU Ventures, Purdue Research Foundation, VisionTech Partners
Source ↗

▶$4.7MraisedDec 2024 · 20 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Keith JohnsExecutive Officer
Karen WursterExecutive Officer, Director
Meng DengDirector
Michael ClaymanDirector

Offering amount: $14.7M
Amount sold: $4.7M
Proceeds to insiders: $219.1K
First sale: Nov 2024
Incorporated: Limited Liability Company, Indiana
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.3MraisedSep 2020 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Meng DengExecutive Officer, Director

Offering amount: $2M
Amount sold: $1.3M
First sale: Aug 2020
Incorporated: Limited Liability Company, Indiana, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Adipopharma14 shared keywordsAdipoPharma is a French biotech company developing PATAS, a first-in-class stapled peptide insulin sensitizer that targets adipocytes to treat insulin resistance, type 2 diabetes, and associated comorbidities. Its adipocyte-focused approach aims to address the root cause of type 2 diabetes, with its lead drug entering clinical trials in 2025.

Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Adipo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Startups to watch: Adipo Therapeutics LLC – Indianapolis Business Journalibj.com · May 2025

Adipo Therapeutics presents positive study results about potential obesity treatment - Newspurdue.edu · Nov 2024

Biopharma startup closes on $1.9M funding round – Inside INdiana Businessinsideindianabusiness.com · Jan 2024

Adipo Therapeutics completes $1.9M seed funding bridge to advance obesity and Type 2 diabetes treatment - Newspurdue.edu · Jan 2024

Support grows for technology aimed at turning bad fat to good fat, to treat millions with obesity, diabetes - Biomedical Engineering - Purdue Universityengineering.purdue.edu · Aug 2020

Frequently asked questions

Who are Adipo Therapeutics's investors?: Adipo Therapeutics's investors include Elevate Ventures, IU Ventures, Riverbend Capital.
How much funding has Adipo Therapeutics raised?: Adipo Therapeutics has disclosed $6M raised across 2 of its 3 known rounds.
Where is Adipo Therapeutics headquartered?: Adipo Therapeutics is headquartered in Indianapolis, US.